Aerie Pharmaceuticals Inc. (AERI) Stock Rating Reaffirmed by Needham & Company LLC
Aerie Pharmaceuticals Inc. (NASDAQ:AERI)‘s stock had its “buy” rating reissued by investment analysts at Needham & Company LLC in a research note issued on Thursday. They presently have a $52.00 target price on the stock, up from their previous target price of $45.00. Needham & Company LLC’s target price points to a potential upside of 49.13% from the company’s current price.
AERI has been the subject of several other reports. Zacks Investment Research downgraded Aerie Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 5th. Brean Capital restated a “buy” rating and set a $48.00 price target on shares of Aerie Pharmaceuticals in a report on Wednesday, September 7th. Raymond James Financial Inc. initiated coverage on Aerie Pharmaceuticals in a report on Tuesday, September 13th. They set an “outperform” rating and a $48.00 price target for the company. Royal Bank Of Canada lifted their price objective on Aerie Pharmaceuticals from $51.00 to $55.00 and gave the stock an “outperform” rating in a report on Thursday. Finally, Cantor Fitzgerald lifted their price objective on Aerie Pharmaceuticals from $44.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Aerie Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $47.56.
Shares of Aerie Pharmaceuticals (NASDAQ:AERI) opened at 34.87 on Thursday. The stock’s 50 day moving average price is $18.88 and its 200 day moving average price is $16.55. The company’s market capitalization is $972.59 million. Aerie Pharmaceuticals has a 12 month low of $10.82 and a 12 month high of $35.25.
Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.02. On average, analysts forecast that Aerie Pharmaceuticals will post ($2.77) EPS for the current year.
In other news, major shareholder Foresite Capital Fund Ii, L.P. bought 250,000 shares of the company’s stock in a transaction on Friday, July 22nd. The shares were acquired at an average cost of $17.50 per share, with a total value of $4,375,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.77% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Essex Investment Management Co. LLC boosted its position in Aerie Pharmaceuticals by 472.3% in the second quarter. Essex Investment Management Co. LLC now owns 107,700 shares of the company’s stock worth $1,896,000 after buying an additional 88,880 shares during the last quarter. Alps Advisors Inc. boosted its position in Aerie Pharmaceuticals by 25.7% in the second quarter. Alps Advisors Inc. now owns 37,268 shares of the company’s stock worth $656,000 after buying an additional 7,618 shares during the last quarter. Iguana Healthcare Management LLC bought a new position in Aerie Pharmaceuticals during the first quarter worth $884,000. Royal Bank of Canada boosted its position in Aerie Pharmaceuticals by 8.4% in the first quarter. Royal Bank of Canada now owns 102,553 shares of the company’s stock worth $1,247,000 after buying an additional 7,982 shares during the last quarter. Finally, Deerfield Management Co. boosted its position in Aerie Pharmaceuticals by 225.9% in the first quarter. Deerfield Management Co. now owns 2,632,482 shares of the company’s stock worth $32,011,000 after buying an additional 1,824,607 shares during the last quarter. 99.66% of the stock is currently owned by hedge funds and other institutional investors.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.